Discussions with leaders: Henryk Barthel talks with Julie Price about her career in advancing neuroimaging to enhance understanding of the brain and neurodegeneration.
Page 499
Theranostics and SBRT in oligometastasis: Kishan and colleagues address the current promise and potential contributions of metastasis-directed therapy in oligometastatic prostate cancer, including radiopharmaceutical and stereotactic body radiation therapies in managing disease.
Page 502
18F-FDG MTV in lymphoma: Barrington and colleagues look at current evidence and promising datasets supporting the use of PET-derived metabolic tumor volume for clinical risk stratification in lymphoma.
Page 510
68Ga-FAPI in invasive lobular cancer: Sahin and colleagues assess the utility of 68Ga-fibroblast activation protein inhibitor PET/CT as an alternative to 18F-FDG PET/CT for staging invasive lobular breast cancer.
Page 512
Early radiation pneumonitis model for NSCLC: Thor and colleagues explore whether published models and pretreatment 18F-FDG PET/CT–derived features can predict radiation pneumonitis within 3 mo after completion of chemoradiation/immunotherapy in stage III non–small cell lung cancer.
Page 520
NSCLC diagnosis and FAP expression: Li and colleagues report on the diagnostic accuracy of 68Ga-labeled fibroblast activation protein inhibitor–04 PET/CT for lymph node metastases in non–small cell lung cancer and identify tumor 68Ga-FAPI-04 uptake correlations with FAP expression.
Page 527
[67Cu]Cu-EB-TATE theranostic and NETs: Njotu and colleagues detail preclinical evaluation of this long-lived somatostatin analog against somatostatin receptor subtype 2–positive neuroendocrine tumors.
Page 533
PSMA PET AUC updates: Hope and Jadvar review current indications for the use of PSMA PET imaging and note additional appropriate use criteria occasioned by the approval of 18F-rh-PSMA-7.3.
Page 540
Pretreatment PSMA PET/CT and 223Ra outcomes: Bosch and colleagues compare outcomes in patients with bone-only metastatic castration-resistant prostate cancer selected for 223Ra-dichloride therapy by baseline imaging with PSMA PET/CT or CT.
Page 541
SUVmax on PSMA PET and γ-probe signal: Berrens and colleagues study correlations between the SUVmax of recurrent prostate cancer lesions on preoperative PSMA PET/CT and their intraoperative counts measured using the Drop-In γ-probe.
Page 548
68Ga-PSMA PET/MRI and PI-RADS 3 classification: Shi and colleagues explore the added value of 68Ga-labeled PSMA-11 PET/MRI in classifying Prostate Imaging Reporting and Data System category 3 lesions to avoid unnecessary biopsies.
Page 555
RECIP 1.0 and [18F]PSMA-1007 PET: Hartrampf and colleagues evaluate the performance of these recently proposed response criteria in predicting overall survival in patients undergoing PSMA-targeted radioligand therapy and imaged with [18F]PSMA-1007 PET/CT.
Page 560
STP with NLME and model selection: Hardiansyah and colleagues investigate the accuracy of single-time-point renal dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects model, and a population-based model selection for 177Lu-labeled PSMA therapy.
Page 566
[177Lu]Lu-DOTA-JR11 and treatment-resistant meningioma: Eigler and colleagues compare the therapeutic index of this new radiolabeled somatostatin receptor antagonist with that of the established receptor agonist [177Lu]Lu-DOTATOC in progressive, standard therapy–refractory meningioma.
Page 573
Theranostic potential in ovarian cancer: Mack and colleagues research the preclinical theranostic promise of a radiolabeled humanized antibody, huAR9.6, in targeting fully glycosylated and hypoglycosylated MUC16 isoforms in ovarian cancer.
Page 580
GPC-3 targeting in liver cancer: Lin and colleagues detail preclinical studies demonstrating the potential of a novel compound containing a macrocyclic peptide binder that can be complexed with different radioisotopes as a theranostic agent for GPC3-positive hepatocellular carcinoma.
Page 586
PSMA-targeted α-radiotherapy: El Fakiri and colleagues report on the design, development, and preclinical evaluation of 211At-based radiopharmaceuticals that use clinically approved PSMA-617 as part of a theranostic strategy in prostate cancer.
Page 593
Internal carotids for PET quantification: Providência and colleagues assess the use of the internal carotids for quantifying brain glucose metabolism before and after partial-volume correction in 18F-FDG PET imaging.
Page 600
Total-body PET/CT applications: Slart and members of the SNMMI Cardiovascular Council provide perspective on potential applications, challenges, opportunities, and remaining challenges of applying PET/CT with a long-axial field of view in cardiovascular disease.
Page 607
PET/CT and angiogenesis in ILD: Porter and colleagues investigate correlations between [18F]FDG uptake and lung biopsy histologic markers in patients with fibrotic interstitial lung disease, highlighting the potential role of vasculature and angiogenesis in fibrosis.
Page 617
Automated PET/CT H&N tumor delineation: Kovacs and colleagues identify and evaluate promising state-of-the-art deep learning methods for 18F-FDG PET gross tumor volume delineation in head and neck cancer.
Page 623
Mutations, RT, and NSCLC: Bourbonne introduce a model enabling prediction of KEAP1/NFE2L2 mutational status using PET/CT-extracted radiomics features to classify patients with non–small cell lung cancer at risk of local relapse after radiotherapy.
Page 630
NSCLC PET biomarkers: Hovhannisyan-Baghdasarian and colleagues assess imaging parameters characterizing the shift of SUVmax toward the lesion edge during tumor progression, their complementarity to conventional PET features, and prognostic value in advanced non–small cell lung cancer.
Page 635
Automated PET/CT tumor quantification: Leung and colleagues report on development of a deep semisupervised transfer learning approach for fully automated, whole-body tumor segmentation and prognosis on PET/CT.
Page 643
uMI Panorama PET/CT: Li and colleagues provide an assessment of the physical performance of this novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies, per the National Electrical Manufacturers Association NU 2-2018 standard.
Page 652
Accomplishments of Saul Hertz: Greenspan and colleagues review the professional milestones of this nuclear medical pioneer in radioactive iodine therapy, including personal and historical context relevant to his legacy in the field.
Page 659
212Pb SPECT/CT in pCa: Griffiths and colleagues present first-in-humans 212Pb SPECT/CT images in a 73-y-old man with metastatic castration-resistant prostate cancer, highlighting potential for postinfusion radiopharmaceutical biodistribution imaging and patient-specific dosimetry for 212Pb-targeted α-therapy.
Page 664
123I-PARPi in neuroendocrine carcinoma: Ndlovu and colleagues describe [123II]-PARP-inhibitor SPECT/CT as a noninvasive tool for whole-body assessment of PARP upregulation in lung small-cell neuroendocrine carcinoma, with implications for patient selection and response prediction in PARPi therapy.
Page 665
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.